N-Butyl Cyanoacrylate

Bile Duct Cancer

Minia UniversitySmall moleculePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

19 Active assets in the Bile Duct Cancer cohort.

Asset / Sponsor	Phase	Rating
Xaliplatin Lisata Therapeutics, Inc.	Phase 2	BB
Cis-Diamminedichloroplatinum Ii Lisata Therapeutics, Inc.	Phase 2	BB
Celecoxib Seoul National University Hospital	Phase 4	B
Pembrolizumab Imugene Limited	Phase 2	B
Fluorouracilum Lisata Therapeutics, Inc.	Phase 2	B

View all 29 →

Same molecule, other indications

N-Butyl Cyanoacrylate is also rated in:

periampullary adenocarcinomaActive

BB

Indicative · Phase 3

64 / 100

duodenum cancerActive

B

Indicative · Phase 3

60 / 100

cholangiocarcinomaActive

CCC

Indicative · Phase 3

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.